Nautilus Biotechnology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Nautilus Biotechnology, Inc. on June 17, 2026. The filing details the voting results for director elections, auditor ratification, and executive compensation advisory votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
- Shareholder Participation: Of 127,078,855 shares outstanding, 85,002,191 shares (approximately 67%) were represented at the meeting.
- Director Elections: Class II nominees Parag Mallick and Farzad Nazem were elected to serve until the 2029 annual meeting. Both received significant support with over 67 million votes "For" each.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 84,937,704 votes "For".
- Executive Compensation (Say on Pay): The advisory vote to approve executive compensation for the fiscal year ended December 31, 2025, passed with 69,994,022 votes "For".
- Vote Frequency: Stockholders advised in favor of holding future Say on Pay votes annually. The next required vote on frequency will occur no later than the 2032 annual meeting.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on business strategy, or specific risk factors. The document is limited to the procedural results of the annual meeting.
Key Facts for Investor Verification
- Confirmation that Parag Mallick and Farzad Nazem have assumed their roles as Class II directors.
- Verification of PricewaterhouseCoopers LLP's engagement for the 2026 fiscal year audit.
- Confirmation that the company will conduct annual Say on Pay votes through 2032.
- Review of the full proxy statement for detailed executive compensation data referenced in the advisory vote.